Last reviewed · How we verify
MECASERMIN RINFABATE
MECASERMIN RINFABATE is a Recombinant protein drug developed by Insmed. It is currently FDA-approved (first approved 2005) for Laron-type isolated somatotropin defect.
At a glance
| Generic name | MECASERMIN RINFABATE |
|---|---|
| Sponsor | Insmed |
| Modality | Recombinant protein |
| Therapeutic area | Other |
| Phase | FDA-approved |
| First approval | 2005 |
Approved indications
- Laron-type isolated somatotropin defect
Common side effects
Key clinical trials
- Peri-operative Dynamics of the Growth Hormone Axis in Subjects With Acromegaly
- ALXN2420 Versus Placebo in Combination With Somatostatin Analogs in Participants With Acromegaly (PHASE2)
- Tesamorelin for Reduction of Liver Fat in Adults With Fatty Liver Disease (Mock Study) (PHASE2)
- System-IGF-1 Pathway and Alzheimer's Disease
- A Study to Assess the Efficacy and Safety of Debio 4126 in Participants With Acromegaly Previously Treated With Somatostatin Analogs (PHASE3)
- A Randomized, Controlled, Safety and Tolerability Study of VRDN-001 in Participants With Thyroid Eye Disease (TED) (PHASE3)
- Impact of Filtration on Autologous Serum Eye Drops (NA)
- Evaluation of (Cardio)Metabolic and Auxological Outcomes of GHD Patients Under rhGH or LAGH With Stratification According to IGF-1 Levels (NA)
Patents
| Patent | Expiry | Type |
|---|---|---|
| Biologic Exclusivity |
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
| FDA Orange Book | Patents + exclusivity |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- MECASERMIN RINFABATE CI brief — competitive landscape report
- MECASERMIN RINFABATE updates RSS · CI watch RSS
- Insmed portfolio CI
Frequently asked questions about MECASERMIN RINFABATE
What is MECASERMIN RINFABATE?
MECASERMIN RINFABATE is a Recombinant protein drug developed by Insmed, indicated for Laron-type isolated somatotropin defect.
What is MECASERMIN RINFABATE used for?
MECASERMIN RINFABATE is indicated for Laron-type isolated somatotropin defect.
Who makes MECASERMIN RINFABATE?
MECASERMIN RINFABATE is developed and marketed by Insmed (see full Insmed pipeline at /company/insmed).
When was MECASERMIN RINFABATE approved?
MECASERMIN RINFABATE was first approved on 2005.
What development phase is MECASERMIN RINFABATE in?
MECASERMIN RINFABATE is FDA-approved (marketed).
Related
- Manufacturer: Insmed — full pipeline
- Therapeutic area: All drugs in Other
- Indication: Drugs for Laron-type isolated somatotropin defect
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing